Irritable Bowel Syndrome News

Patients with irritable bowel syndrome, regardless of subtype, show higher levels of depression and anxiety compared with healthy controls, according to the results of a meta-analysis performed by the Brain-Gut Axis Research Group of the Korean Society of Neurogastroenterology and Motility.

Stress, not dietary intake, contributes to gastrointestinal issues in children with autism spectrum disorder, according to a presentation from the 2017 International Meeting for Autism Research.

The combination of a low FODMAP diet and a prebiotic supplement resulted in significantly greater symptom improvement in patients with irritable bowel syndrome compared with those assigned to a sham diet and placebo in a three-arm parallel randomized controlled trial.

The U.S. Patent and Trademark Office issued allowance of a patent application covering SYN-010, a modified formulation of lovastatin lactone, created by Synthetic Biologics Inc., for the treatment of irritable bowel syndrome with constipation until at least 2034, according to a press release.

Patients with diarrhea-predominant irritable bowel syndrome appear to share a similar “exhaustion” in their T-cells during a symptom flare, differentiating them from other IBS subtypes, according to a letter published in Gut.

The probiotic Bifidobacterium longum improved depression and quality of life, but not anxiety, among individuals with irritable bowel syndrome.

The FDA has accepted Synergy Pharmaceuticals’ supplemental new drug application to add constipation-predominant irritable bowel syndrome as an indication for Trulance, the company announced.

OrphoMed Inc. completed a $39 million Series A financing, the capital of which they will use to accelerate clinical development of its lead candidate, ORP-101, a peripherally acting dimer, for the treatment of irritable bowel syndrome with diarrhea, according to a press release.

CHICAGO — In this exclusive video from Digestive Disease Week, Mark Pimentel, MD, executive director of the Medically Associated Science and Technology program at Cedars Sinai Medical Center in Los Angeles, discusses new developments in understanding the relationship between irritable bowel syndrome and the gut microbiome, and specifically developments in breath testing and emerging microbiome therapeutics shared at the meeting.

CHICAGO —IBgard showed significant efficacy in a combined group of patients with irritable bowel syndrome with both diarrhea and constipation, and patients with diarrhea-predominant IBS, at 24 hours and at 4 weeks, according to data from two posters presented at Digestive Disease Week.